PT-141 and kisspeptin are both studied for sexual function, but through entirely different systems — central melanocortin arousal versus the upstream reproductive-hormone axis.
Research reference only. Not medical advice, prescribing guidance, or a product recommendation.
| Dimension | PT-141 | Kisspeptin |
|---|---|---|
| Structure | Cyclic heptapeptide (α-MSH analog) | Hypothalamic neuropeptide |
| Receptor | Melanocortin MC3R / MC4R (CNS) | KISS1R / GPR54 (GnRH neurons) |
| Pathway | Central arousal, hormone-independent | GnRH → LH / FSH → sex steroids |
| Research framing | Acute central desire | Hormonal-axis regulation |
| Onset | Acute | Physiologic (axis-driven) |
| FDA status | Approved (Vyleesi, HSDD in premenopausal women) | Investigational |
| Characterizing work | Molinoff / Diamond et al., 2003 | KISS1R / GnRH endocrinology |
PT-141 (bremelanotide) is a cyclic α-MSH analog that acts in the brain on melanocortin MC3R / MC4R receptors to generate sexual arousal independent of the reproductive hormone axis — an acute, central, on-demand mechanism (Molinoff / Diamond et al., 2003). It is FDA-approved (Vyleesi) for hypoactive sexual desire disorder in premenopausal women.
Kisspeptin works one level upstream: it signals through KISS1R / GPR54 on GnRH neurons, increasing GnRH pulsatility and downstream LH, FSH, and sex-steroid production — and, via limbic KISS1R expression, contributes directly to sexual motivation. So PT-141 addresses acute central arousal, while kisspeptin addresses the hormonal regulation of the reproductive axis.
These answer different research questions. PT-141 is the tool for acute central arousal and is the only one of the two with an FDA approval; kisspeptin is the tool for probing or restoring the GnRH hormone axis and remains investigational. They are not interchangeable, and in principle act on complementary parts of the same overall system.
PT-141 (bremelanotide) is a melanocortin MC3R/MC4R agonist that produces acute central sexual arousal independent of reproductive hormones. Kisspeptin acts on KISS1R/GPR54 on GnRH neurons to drive the reproductive hormone axis (GnRH, LH, FSH, sex steroids). Different systems, different research uses.
Yes — bremelanotide (PT-141) is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Kisspeptin remains investigational.
Kisspeptin stimulates GnRH pulsatility and downstream LH / FSH and sex-steroid secretion, and KISS1R is also expressed in limbic brain regions, which is studied as a direct route to sexual motivation.
No — this page is a research and educational reference, not medical advice or a dosing protocol.